Mentioned On
Episode Mentions
Bloomberg Intelligence · Jul 16, 2026
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker
“Psychedelic drug development company in treatment-resistant depression and anxiety therapeutic area”
Psychedelic Drug Development and RegulationEli Lilly M&A Strategy and Contingent Value RightsPCSK9 Inhibitors and Cholesterol Management
View Analysis
Making Sense with Sam Harris · May 29, 2026
#478 — The Psychedelic Mind
“Conducting Phase 2B and Phase 3 trials for psilocybin therapy using traditional clinical approaches”
Psychedelic therapy protocolsFDA drug approval processClinical trial design
View Analysis
CNBC's "Fast Money" · Apr 24, 2026
Intel Posts Best Day Since 1987 and Counting Down to Big Tech Results 4/24/26
“Psychedelic stock rallying on FDA fast-track approval for mental illness research”
Semiconductor Supply Chain and CPU DemandAI Infrastructure Investment and CapEx CyclesFed Leadership Confirmation and Monetary Policy
View Analysis
Squawk Pod · Apr 22, 2026
Gone Tripping: United CEO Scott Kirby & Psychedelic Therapy 4/22/26
“Psychedelics company developing clinical treatments; Christian Angemeyer is a seed investor”
Airline Industry Consolidation and Merger RegulationJet Fuel Price Volatility and Airline Pricing StrategyPsychedelic-Assisted Therapy Clinical Efficacy
View Analysis
Motley Fool Money · Apr 12, 2026
The Psychedelic Revolution
“Publicly traded psychedelic biotech (CNPS) advancing phase 3 trials for COMP360 psilocybin treatment with recent 23% stock jump”
Psychedelic-Assisted Therapy Clinical EfficacyTreatment-Resistant Depression Market OpportunityFDA Approval Pathways for Psychedelic Compounds
View Analysis